



SUMMARY OF CHANGES:

INSTRUMENT NOS. 1 to 20 of 2022

Statements of Principles Nos. 1 to 20 of 2022 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 24 December 2021. The day of commencement as specified in each of these Instruments is 31 January 2022.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from <http://www.legislation.gov.au>.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on the Authority's website at <http://www.rma.gov.au>.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is also available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar
Repatriation Medical Authority
GPO Box 1014
Brisbane Qld 4001

T +61 7 3815 9404
F +61 7 3815 9412
E info@rma.gov.au

5 January 2022

SUMMARY OF CHANGES

| Instr. No. | Title | Date of Commencement | ICD-10-AM Code |
|----------------|--|----------------------|--|
| REPEALS | | | |
| 1 & 2/2022 | Hashimoto thyroiditis | 31/01/2022 | E03.4, E03.5, E06.3 |
| 3 & 4/2022 | hypothyroidism | 31/01/2022 | Nil |
| 5 & 6/2022 | hyperthyroidism and thyrotoxicosis | 31/01/2022 | Nil |
| 7 & 8/2022 | Graves disease | 31/01/2022 | E05.0, E05.5 |
| 9 & 10/2022 | goitre | 31/01/2022 | Nil |
| 11 & 12/2022 | narcolepsy | 31/01/2022 | G47.4 |
| 13 & 14/2022 | aortic stenosis | 31/01/2022 | I35.0, I35.2 |
| 15 & 16/2022 | colorectal adenoma | 31/01/2022 | D12.0, D12.1, D12.2, D12.3, D12.4, D12.5, D12.7, |
| 17 & 18/2022 | gingivitis | 31/01/2022 | A69.1, K05.0, K05.1 |
| 19 & 20/2022 | malignant neoplasm of the colon and rectum | 31/01/2022 | C18, C19, C20 |

Note:

1. The investigation concerning 'Hashimoto's thyroiditis' has resulted in the determination of Statements of Principles concerning **Hashimoto thyroiditis**.
2. The investigation concerning 'Graves' disease' has resulted in the determination of Statements of Principles concerning **Graves disease**.
3. The investigation concerning 'malignant neoplasm of the colorectum' has resulted in the determination of Statements of Principles concerning **malignant neoplasm of the colon and rectum**.

SUMMARY OF CHANGES

| | | |
|-----------------------|------------------------------|--|
| <p>1 & 2/2022</p> | <p>Hashimoto thyroiditis</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>Hashimoto's thyroiditis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 1/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'Hashimoto's thyroiditis' to 'Hashimoto thyroiditis'; • revising the definition of 'Hashimoto thyroiditis' in subsection 7(2); • revising ICD-10-AM codes for 'Hashimoto thyroiditis' in subsection 7(3); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factors in subsections 9(1) and 9(11) concerning having iodine excess; • revising the factor in subsection 9(2) concerning taking a drug from the Specified List 1 of drugs; • revising the factors in subsections 9(4) and 9(14) concerning having received iodine-131 (radioactive iodine) treatment; • revising the factors in subsections 9(5) and 9(15) concerning hepatitis C virus; • new factors in subsections 9(6) and 9(16) concerning being obese; • new factors in subsections 9(7) and 9(17) concerning permanently ceasing to smoke; • new factors in subsections 9(8) and 9(18) concerning having postpartum thyroiditis; • new factors in subsections 9(9) and 9(19) concerning having posttraumatic stress disorder; • new factor in subsection 9(10) concerning for Hashimoto thyroiditis first presenting as myxoedema coma only, having an acute precipitating event, for clinical onset only; • revising the factor in subsection 9(12) concerning taking a drug from the Specified List 2 of drugs; • new factor in subsection 9(20) concerning being pregnant or within the 12 months postpartum, for clinical worsening only; • new factor in subsection 9(21) concerning for myxoedema coma only, having an acute precipitating event, for clinical worsening only; • deleting the factors concerning having received a cumulative equivalent dose of ionising radiation as these are covered by the factors in subsections 9(3) and 9(13) concerning undergoing a course of therapeutic radiation for cancer; • new definitions of 'acute precipitating event', 'being obese', 'BMI', 'iodine excess', 'MRCA', 'myxoedema coma', 'one pack-year', 'regular smoking habit as specified', 'Specified List 1 of drugs', 'Specified List 2 of drugs' and 'VEA' in Schedule 1 - Dictionary; • revising the definition of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'a drug from the specified list', 'cumulative equivalent dose' and 'having iodine excess'. <p>For BoP SoP (Instrument No. 2/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'Hashimoto's thyroiditis' to 'Hashimoto thyroiditis'; • revising the definition of 'Hashimoto thyroiditis' in subsection 7(2); • revising ICD-10-AM codes for 'Hashimoto thyroiditis' in subsection 7(3); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factors in subsections 9(1) and 9(8) concerning having iodine excess; • revising the factor in subsection 9(2) concerning taking a drug from the Specified List 1 of drugs; • revising the factors in subsections 9(4) and 9(11) concerning having received iodine-131 (radioactive iodine) treatment; • new factors in subsections 9(5) and 9(12) concerning being obese; • new factors in subsections 9(6) and 9(13) concerning having postpartum thyroiditis; • new factor in subsection 9(7) concerning for Hashimoto thyroiditis first presenting as myxoedema coma only, having an acute precipitating event, for clinical onset only; • revising the factor in subsection 9(9) concerning taking a drug from the Specified List 2 of drugs; |
|-----------------------|------------------------------|--|

SUMMARY OF CHANGES

| | | |
|-----------------------|-----------------------|--|
| | | <ul style="list-style-type: none"> • new factor in subsection 9(14) concerning being pregnant or within the 12 months postpartum, for clinical worsening only; • new factor in subsection 9(15) concerning for myxoedema coma only, having an acute precipitating event, for clinical worsening only; • deleting the factors concerning having received a cumulative equivalent dose of ionising radiation as these are covered by the factors in subsections 9(3) and 9(10) concerning undergoing a course of therapeutic radiation for cancer; • new definitions of 'acute precipitating event', 'being obese', 'BMI', 'iodine excess', 'MRCA', 'myxoedema coma', 'Specified List 1 of drugs', 'Specified List 2 of drugs' and 'VEA' in Schedule 1 - Dictionary; • revising the definition of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'cumulative equivalent dose' and having iodine excess'. <p>The determining of these Instruments finalises the investigation in relation to Hashimoto's thyroiditis as advertised in the Government Notices Gazette of 9 March 2021.</p> |
| <p>3 & 4/2022</p> | <p>hypothyroidism</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>hypothyroidism</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 3/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'hypothyroidism' in subsection 7(2); • revising the factors in subsections 9(1) and 9(21) concerning having iodine deficiency; • revising the factors in subsections 9(2) and 9(22) concerning having iodine excess; • revising the factors in subsections 9(4) and 9(24) concerning taking a drug from the specified list of drugs; • new factors in subsections 9(5) and 9(25) concerning taking minocycline; • revising the factors in subsections 9(6) and 9(26) concerning taking a drug containing iodine; • new factors in subsections 9(7) and 9(27) concerning taking amiodarone; • revising the factors in subsections 9(8) and 9(29) concerning being pregnant or within the 12 months postpartum; • revising the factors in subsections 9(9) and 9(30) concerning having a form of thyroiditis from the specified list of forms of thyroiditis; • revising the factors in subsections 9(11) and 9(32) concerning having received iodine-131 (radioactive iodine) treatment; • new factors in subsections 9(13) and 9(34) concerning having a disease involving the thyroid gland from the specified list of diseases; • new factors in subsections 9(15) and 9(36) concerning having a type 3 deiodinase-overexpressing neoplasm; • revising the factors in subsections 9(16) and 9(37) concerning having hypopituitarism involving deficiency of thyroid-stimulating hormone; • revising the factors in subsections 9(17) and 9(38) concerning having chronic kidney disease; • new factors in subsections 9(18) and 9(39) concerning having hepatitis C virus infection; • new factors in subsections 9(19) and 9(40) concerning being obese; • new factors in subsections 9(20) and 9(41) concerning having an acute precipitating event, for myxoedema coma only; • new factor in subsection 9(28) concerning taking a drug that increases the requirement of thyroid hormone replacement therapy, for clinical worsening only; • deleting the factors concerning having received ionising radiation, as these are covered by the factors in subsections 9(10) and 9(31) concerning undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation; • deleting the factors concerning having a chronic infiltrative or infectious disease of the thyroid gland, as these are now covered by the factors in subsections 9(13) and 9(34) concerning having a disease involving the thyroid gland from the specified list of diseases; • new definitions of 'abnormality of kidney structure or function', 'acute precipitating event', 'being obese', 'BMI', 'chronic kidney disease', 'iodine deficiency', 'iodine excess', 'MRCA', |

SUMMARY OF CHANGES

| | | |
|------------|------------------------------------|--|
| | | <p>'myxoedema coma', 'specified list of diseases', 'specified list of drugs', 'specified list of forms of thyroiditis' and 'VEA' in Schedule 1 - Dictionary;</p> <ul style="list-style-type: none"> revising the definition of 'relevant service' in Schedule 1 - Dictionary; and deleting the definitions of 'a chronic infiltrative or infectious disease', 'a drug or a drug from a class of drugs from the specified list', 'a specified form of thyroiditis', 'being iodine deficient', 'cumulative equivalent dose', 'having iodine excess' and 'the recommended iodine intake'. <p>For BoP SoP (Instrument No. 4/2022)</p> <ul style="list-style-type: none"> adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'hypothyroidism' in subsection 7(2); revising the factors in subsections 9(1) and 9(18) concerning having iodine deficiency; revising the factors in subsections 9(2) and 9(19) concerning having iodine excess; revising the factors in subsections 9(4) and 9(21) concerning taking a drug from the specified list of drugs; revising the factors in subsections 9(5) and 9(22) concerning taking a drug containing iodine; new factors in subsections 9(6) and 9(23) concerning taking amiodarone; revising the factors in subsections 9(7) and 9(25) concerning being pregnant or within the 12 months postpartum; revising the factors in subsections 9(8) and 9(26) concerning having a form of thyroiditis from the specified list of forms of thyroiditis; revising the factors in subsections 9(10) and 9(28) concerning having received iodine-131 (radioactive iodine); new factors in subsections 9(12) and 9(30) concerning having a disease involving the thyroid gland from the specified list of diseases; new factors in subsections 9(14) and 9(32) concerning having a type 3 deiodinase-overexpressing neoplasm; revising the factors in subsections 9(15) and 9(33) concerning having hypopituitarism involving deficiency of thyroid-stimulating hormone; new factors in subsections 9(16) and 9(34) concerning being obese; new factors in subsections 9(17) and 9(35) concerning having an acute precipitating event, for myxoedema coma only; new factor in subsection 9(24) concerning taking a drug that increases the requirement of thyroid hormone replacement therapy, for clinical worsening only; deleting the factors concerning having received ionising radiation, as these are covered by the factors in subsections 9(9) and 9(27) concerning undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation; deleting the factors concerning having a chronic infiltrative or infectious disease of the thyroid gland, as these are now covered by the factors in subsections 9(12) and 9(30) concerning having a disease involving the thyroid gland from the specified list of diseases; new definitions of 'acute precipitating event', 'being obese', 'BMI', 'iodine deficiency', 'iodine excess', 'MRCA', 'myxoedema coma', 'specified list of diseases', 'specified list of drugs', 'specified list of forms of thyroiditis' and 'VEA' in Schedule 1 - Dictionary; revising the definition of 'relevant service' in Schedule 1 - Dictionary; and deleting the definitions of 'a chronic infiltrative or infectious disease', 'a drug or a drug from a class of drugs from the specified list', 'a specified form of thyroiditis', 'being iodine deficient', 'cumulative equivalent dose', 'having iodine excess' and 'the recommended iodine intake'. <p>The determining of these Instruments finalises the investigation in relation to <i>hypothyroidism</i> as advertised in the Government Notices Gazette of 5 January 2021.</p> |
| 5 & 6/2022 | hyperthyroidism and thyrotoxicosis | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>hyperthyroidism and thyrotoxicosis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH and BoP SoPs (Instrument Nos. 5 & 6/2022)</p> <ul style="list-style-type: none"> adopting the latest revised Instrument format, which commenced in 2015; specifying a day of commencement for the Instrument in section 2; revising the definition of 'hyperthyroidism' in subsection 7(2); |

SUMMARY OF CHANGES

| | | |
|------------|----------------|---|
| | | <ul style="list-style-type: none"> • revising the definition of 'thyrotoxicosis' in subsection 7(3); • revising the factors in subsections 9(1) and 9(12) concerning having iodine excess; • revising the factors in subsections 9(3) and 9(14) concerning taking amiodarone; • revising the factors in subsections 9(4) and 9(15) concerning taking a drug from the specified list of drugs; • new factors in subsections 9(5) and 9(16) concerning taking minocycline; • new factors in subsections 9(6) and 9(17) concerning taking a drug containing iodine; • revising the factors in subsections 9(8) and 9(19) concerning having a chorionic gonadotrophin-secreting neoplasm, by the inclusion of a note; • new factors in subsections 9(9) and 9(20) concerning having a primary or metastatic neoplasm involving the thyroid gland; • new factors in subsections 9(10) and 9(21) concerning having an acute, severe stressor, for thyrotoxic crisis only; • revising the factors in paragraphs 9(11)(a) and 9(22)(a) concerning having struma ovarii, for thyrotoxicosis only; • new factors in paragraphs 9(11)(b) and 9(22)(b) concerning having metastatic thyroid carcinoma containing functional thyroid tissue, for thyrotoxicosis only; • revising the factors in paragraphs 9(11)(c) and 9(22)(c) concerning having a form of thyroiditis from the specified list of forms of thyroiditis, for thyrotoxicosis only; • revising the factors in paragraphs 9(11)(d) and 9(22)(d) concerning having trauma involving the thyroid gland, for thyrotoxicosis only; • revising the factors in paragraphs 9(11)(e) and 9(22)(e) concerning ingesting excess thyroid hormone, for thyrotoxicosis only; • deleting the factor concerning having an acute illness or undergoing surgery, for worsening only, as this is now covered by the factors in subsections 9(10) and 9(21) concerning having an acute, severe stressor, for thyrotoxic crisis only; • new definitions of 'acute, severe stressor', 'iodine excess', 'MRCA', 'specified list of drugs', 'specified list of forms of thyroiditis', 'thyrotoxic crisis' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'chorionic gonadotrophin-secreting neoplasm', 'relevant service' and 'trauma involving the thyroid gland' in Schedule 1 - Dictionary; and • deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a specified form of thyroiditis' and 'having iodine excess'. <p>The determining of these Instruments finalises the investigation in relation to hyperthyroidism and thyrotoxicosis as advertised in the Government Notices Gazette of 5 January 2021.</p> |
| 7 & 8/2022 | Graves disease | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>Graves' disease</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p><i>For RH and BoP SoPs (Instrument Nos. 7 & 8/2022)</i></p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'Graves disease' in subsection 7(2); • revising ICD-10-AM codes for 'Graves disease' in subsection 7(3); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factors in subsections 9(1) and 9(12) concerning having iodine excess; • revising the factors in subsections 9(2) and 9(13) concerning taking a drug from the specified list of drugs; • new factors in subsections 9(3) and 9(14) concerning being treated with alemtuzumab or antithymocyte globulin; • new factor in subsection 9(4) concerning taking amiodarone, for clinical onset; • revising the factors in subsections 9(5) and 9(16) concerning undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation; • revising the factors in subsections 9(6) and 9(17) concerning having received iodine-131 (radioactive iodine) for the treatment of nodular goitre; • revising the factors in subsections 9(7) and 9(18) concerning having smoked tobacco products; |

SUMMARY OF CHANGES

| | | |
|----------------------------|---------------|---|
| | | <ul style="list-style-type: none"> • new factors in subsections 9(8) and 9(19) concerning being pregnant or within the 18 months postpartum; • new factors in subsections 9(9) and 9(20) concerning having ethanol injection into the thyroid gland for the treatment of a thyroid adenoma; • new factors in subsections 9(10) and 9(21) concerning having trauma to the eye; • new factors in subsections 9(11) and 9(22) concerning having an acute, severe stressor, for thyrotoxic crisis only; • revising the factor in subsection 9(15) concerning taking amiodarone, for clinical worsening; • deleting the factors concerning having received ionising radiation, as these are covered by the factors in subsections 9(5) and 9(16) concerning undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation; • new definitions of 'acute, severe stressor', 'iodine excess', 'MRCA', 'one pack-year', 'specified list of drugs', 'thyrotoxic crisis' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'cumulative equivalent dose', 'having iodine excess' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. <p>The determining of these Instruments finalises the investigation in relation to <i>Graves' disease</i> advertised in the Government Notices Gazette of 5 January 2021.</p> |
| <p>9 & 10/2022</p> | <p>goitre</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>goitre</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p><i>For RH SoP (Instrument No. 9/2022)</i></p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'goitre' in subsection 7(2); • revising the factors in subsections 9(1) and 9(14) concerning having iodine deficiency; • revising the factors in subsections 9(2) and 9(15) concerning having iodine excess; • revising the factors in subsections 9(3) and 9(16) concerning taking a drug from the specified list of drugs; • new factors in subsections 9(4) and 9(17) concerning taking a drug containing at least 10 milligrams of iodine; • revising the factors in subsections 9(5) and 9(18) concerning taking amiodarone; • revising the factors in subsections 9(7) and 9(20) concerning having smoked tobacco products; • revising the factors in subsections 9(8) and 9(21) concerning having a form of thyroiditis from the specified list of forms of thyroiditis; • new factors in subsections 9(9) and 9(22) concerning having a disease from the specified list of diseases involving the thyroid gland; • revising the factors in subsections 9(10) and 9(23) concerning having chronic renal failure; • new factors in subsections 9(11) and 9(24) concerning having a thyroid-stimulating hormone-secreting pituitary adenoma; • revising the factors in subsections 9(12) and 9(25) concerning having received ionising radiation or undergoing a course of therapeutic radiation for cancer, for thyroid adenoma and multinodular goitre only; • new factors in subsections 9(13) and 9(26) concerning having an acute, severe stressor, for thyrotoxic crisis only; • deleting the factors concerning having a chronic infiltrative or infectious disease of the thyroid gland, as these are now covered by the factors in subsections 9(9) and 9(22) concerning having a disease from the specified list of diseases involving the thyroid gland; • new definitions of 'acute, severe stressor', 'chronic renal failure', 'iodine deficiency', 'iodine excess', 'MRCA', 'one pack-year', 'specified list of diseases', 'specified list of drugs', 'specified list of forms of thyroiditis', 'thyrotoxic crisis' and 'VEA' in Schedule 1 - Dictionary; • revising the definition of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a specified form of thyroiditis', 'being iodine deficient', 'having iodine excess', 'pack-years of |

SUMMARY OF CHANGES

| | | |
|-----------------------------|-------------------|---|
| | | <p>cigarettes, or the equivalent thereof in other tobacco products' and 'the recommended iodine intake'.</p> <p>For BoP SoP (Instrument No. 10/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a date of effect for the Instrument in section 2; • revising the definition of 'goitre' in subsection 7(2); • revising the factors in subsections 9(1) and 9(13) concerning having iodine deficiency; • revising the factors in subsections 9(2) and 9(14) concerning having iodine excess; • revising the factors in subsections 9(3) and 9(15) concerning taking a drug from the specified list of drugs; • new factors in subsections 9(4) and 9(16) concerning taking a drug containing at least 10 milligrams of iodine; • revising the factors in subsections 9(5) and 9(17) concerning taking amiodarone; • revising the factors in subsections 9(7) and 9(19) concerning having smoked tobacco products; • revising the factors in subsections 9(8) and 9(20) concerning having a form of thyroiditis from the specified list of forms of thyroiditis; • new factors in subsections 9(9) and 9(21) concerning having a disease from the specified list of diseases involving the thyroid gland; • new factors in subsections 9(10) and 9(22) concerning having a thyroid-stimulating hormone-secreting pituitary adenoma; • revising the factors in subsections 9(11) and 9(23) concerning having received ionising radiation or undergoing a course of therapeutic radiation for cancer, for thyroid adenoma and multinodular goitre only; • deleting the factors concerning having a chronic infiltrative or infectious disease of the thyroid gland, as these are now covered by the factors in subsections 9(9) and 9(21) concerning having a disease from the specified list of diseases involving the thyroid gland; • new definitions of 'acute, severe stressor', 'iodine deficiency', 'iodine excess', 'MRCA', 'one pack-year', 'specified list of diseases', 'specified list of drugs', 'specified list of forms of thyroiditis', 'thyrotoxic crisis' and 'VEA' in Schedule 1 - Dictionary; • revising the definition of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a specified form of thyroiditis', 'being iodine deficient', 'having iodine excess', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'the recommended iodine intake'. <p>The determining of these Instruments finalises the investigation in relation to <i>goitre</i> as advertised in the Government Notices Gazette of 5 January 2021.</p> |
| <p>11 & 12/2022</p> | <p>narcolepsy</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 4 May 2021 concerning <i>narcolepsy</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 11/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'narcolepsy' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factor in subsection 9(1) concerning having concussion or moderate to severe traumatic brain injury, for clinical onset; • revising the factor in subsection 9(2) concerning having a neurosurgical procedure involving the hypothalamus, midbrain or brainstem, for clinical onset; • revising the factor in subsection 9(3) concerning undergoing a course of therapeutic radiation for cancer, for clinical onset; • revising the factor in subsection 9(4) concerning having a neurological disease, neurodegenerative disease or a paraneoplastic neurological syndrome, for clinical onset; • new factors in subsections 9(5) and 9(13) concerning having a benign or malignant neoplasm or having a non-malignant space occupying lesion; • revising the factor in subsection 9(6) concerning receiving the adjuvanted influenza H1N1 vaccine Pandemrix™; |

SUMMARY OF CHANGES

- new factor in subsections 9(7) and 9(15) concerning having infection with H1N1 influenza virus;
- revising the factor in subsection 9(8) concerning having infection of the pharynx with *Streptococcus pyogenes*;
- new factor in subsection 9(9) concerning having concussion or moderate to severe traumatic brain injury, for clinical worsening;
- new factor in subsection 9(10) concerning having a neurosurgical procedure involving the hypothalamus, midbrain or brainstem, for clinical worsening;
- new factor in subsection 9(11) concerning undergoing a course of therapeutic radiation for cancer, for clinical worsening;
- new factor in subsection 9(12) concerning having a neurological disease, neurodegenerative disease or a paraneoplastic neurological syndrome, for clinical worsening;
- new factor in subsection 9(14) concerning receiving the adjuvanted influenza H1N1 vaccine Pandemrix™;
- revising the factor in subsection 9(16) concerning having infection of the pharynx with *Streptococcus pyogenes*;
- deleting the factors concerning having received a cumulative equivalent dose of ionising radiation as these are covered by the factors in subsections 9(3) and 9(11) concerning undergoing a course of therapeutic radiation for cancer;
- new definitions of 'cataplexy', 'hypnagogic hallucinations', 'MRCA', 'sleep paralysis' and 'VEA'; in Schedule 1 - Dictionary;
- revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a specified neurological disorder' and 'cumulative equivalent dose'.

For BoP SoP (Instrument No. 12/2022)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'narcolepsy' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning having concussion or moderate to severe traumatic brain injury, for clinical onset;
- revising the factor in subsection 9(2) concerning having a neurosurgical procedure involving the hypothalamus, midbrain or brainstem, for clinical onset;
- revising the factor in subsection 9(3) concerning undergoing a course of therapeutic radiation for cancer, for clinical onset;
- revising the factor in subsection 9(4) concerning having a neurological disease, neurodegenerative disease or a paraneoplastic neurological syndrome, for clinical onset;
- new factors in subsections 9(5) and 9(12) concerning having a benign or malignant neoplasm or having a non-malignant space occupying lesion;
- new factors in subsections 9(6) and 9(13) concerning receiving the adjuvanted influenza H1N1 vaccine Pandemrix™;
- new factors in subsections 9(7) and 9(14) concerning having infection of the pharynx with *Streptococcus pyogenes*;
- new factor in subsection 9(8) concerning having concussion or moderate to severe traumatic brain injury, for clinical worsening;
- new factor in subsection 9(9) concerning having a neurosurgical procedure involving the hypothalamus, midbrain or brainstem, for clinical worsening;
- new factor in subsection 9(10) concerning undergoing a course of therapeutic radiation for cancer, for clinical worsening;
- new factor in subsection 9(11) concerning having a neurological disease, neurodegenerative disease or a paraneoplastic neurological syndrome, for clinical worsening;
- deleting the factors concerning having received a cumulative equivalent dose of ionising radiation as these are covered by the factors in subsections 9(3) and 9(10) concerning undergoing a course of therapeutic radiation for cancer;
- new definitions of 'cataplexy', 'hypnagogic hallucinations', 'MRCA', 'sleep paralysis' and 'VEA'; in Schedule 1 - Dictionary;
- revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a specified neurological disorder' and 'cumulative equivalent dose'.

The determining of these Instruments finalises the investigation in relation to narcolepsy as advertised in the Government Notices Gazette of 4 May 2021.

SUMMARY OF CHANGES13 &
14/2022

aortic stenosis

These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning *aortic stenosis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

For RH SoP (Instrument No. 13/2022)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'aortic stenosis' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(2) and 9(14) concerning having a systemic autoimmune connective tissue disease;
- new factors in subsections 9(3) and 9(15) concerning having chronic kidney disease;
- revising the factors in subsections 9(5) and 9(17) concerning having dyslipidaemia, by the inclusion of a note;
- new factors in subsections 9(6) and 9(18) concerning having diabetes mellitus;
- new factors in subsections 9(7) and 9(19) concerning being overweight or obese;
- revising the factors in subsections 9(8) and 9(20) concerning having smoked tobacco products;
- revising the factors in subsections 9(9) and 9(21) concerning having received ionising radiation to the heart, by the inclusion of a note;
- new factors in subsections 9(10) and 9(22) concerning undergoing a course of therapeutic radiation for cancer, where the heart was in the field of radiation;
- new factor in subsection 9(25) concerning being pregnant, for clinical worsening only;
- new factor in subsection 9(26) concerning having surgery requiring a general, spinal or epidural anaesthetic, for clinical worsening only and for symptomatic or severe aortic stenosis only;
- deleting the factors concerning having systemic lupus erythematosus or rheumatoid arthritis, as these are now covered by the factors in subsections 9(2) and 9(14) concerning having a systemic autoimmune connective tissue disease;
- deleting the factors concerning having chronic renal disease requiring renal transplantation or dialysis, as these are now covered by the factors in subsections 9(3) and 9(15) concerning having chronic kidney disease;
- deleting the factors concerning having alkaptonuria;
- new definitions of 'abnormality of kidney structure or function', 'being overweight or obese', 'BMI', 'chronic kidney disease', 'MRCA', 'one pack-year', 'severe aortic stenosis' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'dyslipidaemia' and 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'infective endocarditis' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

For BoP SoP (Instrument No. 14/2022)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'aortic stenosis' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(2) and 9(12) concerning having a systemic autoimmune connective tissue disease;
- new factors in subsections 9(3) and 9(13) concerning having chronic kidney disease;
- new factors in subsections 9(4) and 9(14) concerning having hypertension;
- revising the factors in subsections 9(5) and 9(15) concerning having dyslipidaemia, by the inclusion of a note;
- new factors in subsections 9(6) and 9(16) concerning having diabetes mellitus;
- new factors in subsections 9(7) and 9(17) concerning being overweight or obese;
- new factors in subsections 9(8) and 9(18) concerning having smoked tobacco products;
- revising the factors in subsections 9(9) and 9(19) concerning having received ionising radiation to the heart, by the inclusion of a note;
- new factors in subsections 9(10) and 9(20) concerning undergoing a course of therapeutic radiation for cancer, where the heart was in the field of radiation;

SUMMARY OF CHANGES

| | | |
|-----------------------------|---------------------------|--|
| | | <ul style="list-style-type: none"> • new factor in subsection 9(21) concerning being pregnant, for clinical worsening only; • new factor in subsection 9(22) concerning having surgery requiring a general, spinal or epidural anaesthetic, for clinical worsening only and for symptomatic or severe aortic stenosis only; • deleting the factors concerning having systemic lupus erythematosus or rheumatoid arthritis, as these are now covered by the factors in subsections 9(2) and 9(12) concerning having a systemic autoimmune connective tissue disease; • deleting the factors concerning having chronic renal disease requiring renal transplantation or dialysis, as these are now covered by the factors in subsections 9(3) and 9(13) concerning having chronic kidney disease; • new definitions of 'abnormality of kidney structure or function', 'being overweight or obese', 'BMI', 'chronic kidney disease', 'MRCA', 'one pack-year', 'severe aortic stenosis' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'dyslipidaemia' and 'relevant service' in Schedule 1 - Dictionary; and • deleting the definition of 'infective endocarditis'. <p>The determining of these Instruments finalises the investigation in relation to aortic stenosis as advertised in the Government Notices Gazette of 5 January 2021.</p> |
| <p>15 & 16/2022</p> | <p>colorectal adenoma</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>colorectal adenoma</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 15/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'colorectal adenoma' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only; • revising the factor in subsection 9(2) concerning consuming alcohol, for clinical onset only; • revising the factor in subsection 9(3) concerning being overweight or obese, for clinical onset only; • revising the factor in subsection 9(5) concerning an inability to consume fibre in food, for clinical onset only; • new factor in subsection 9(6) concerning having a solid organ transplant, for clinical onset only; • new factor in subsection 9(7) concerning having a ureterosigmoidostomy involving the affected part of the colorectum, for clinical onset only; • revising the factor in paragraph 9(8)(a) concerning an inability to undertake physical activity, for clinical onset of adenoma of the colon only; • revising the factor in paragraph 9(8)(b) concerning having acromegaly, for clinical onset of adenoma of the colon only, by the inclusion of a note; • revising the factor in paragraph 9(8)(c) concerning consuming red meat, for clinical onset of adenoma of the colon only; • revising the factor in paragraph 9(8)(d) concerning consuming processed meat product, for clinical onset of adenoma of the colon only; • new factor in paragraph 9(8)(e) concerning an inability to consume fruit and vegetables, for clinical onset of adenoma of the colon only; • deleting the factor concerning having ulcerative colitis, for clinical onset only; • deleting the factor concerning having Crohn's disease of the colorectum, for clinical onset only; • deleting the factor concerning an inability to consume dairy milk, for clinical onset only; • deleting the factor concerning an inability to consume folate in food, for clinical onset only; • new definitions of 'being overweight or obese', 'BMI', 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'red meat' and 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'alcohol', 'being obese', 'folate in food' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. |

SUMMARY OF CHANGES

| | | |
|-----------------------------|-------------------|--|
| | | <p>For BoP SoP (Instrument No. 16/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'colorectal adenoma' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only; • revising the factor in subsection 9(2) concerning consuming alcohol, for clinical onset only; • revising the factor in subsection 9(3) concerning being obese, for clinical onset only; • new factor in subsection 9(4) concerning having diabetes mellitus, for clinical onset only; • new factor in subsection 9(5) concerning an inability to consume fibre in food, for clinical onset only; • revising the factor in paragraph 9(6)(a) concerning an inability to undertake physical activity, for clinical onset of adenoma of the colon only; • new factor in subsection 9(6)(b) concerning consuming red meat, for clinical onset of adenoma of the colon only; • new factor in subsection 9(6)(c) concerning consuming processed meat product, for clinical onset of adenoma of the colon only; • new definitions of 'BMI', 'fibre in food', 'MRCA', 'one pack-year', 'processed meat product', 'red meat' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'being obese' and 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'alcohol' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. <p>The determining of these Instruments finalises the investigation in relation to colorectal adenoma as advertised in the Government Notices Gazette of 5 January 2021.</p> |
| <p>17 & 18/2022</p> | <p>gingivitis</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>gingivitis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 17/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'gingivitis' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factor in subsections 9(1) and 9(22) concerning being prevented from cleaning the teeth, including toothbrushing and interdental cleansing; • revising the factors in subsections 9(2) and 9(23) concerning having a foreign body embedded in the affected region of the gums, by the inclusion of a note; • revising the factors in subsections 9(3) and 9(24) concerning having trauma to the affected region of the gums; • revising the factors in subsections 9(4) and 9(25) concerning having direct exposure of the affected area to an irritant substance, by the inclusion of a note; • new factors in subsections 9(5) and 9(26) concerning having direct exposure of the affected area to an allergen; • revising the factors in subsections 9(6) and 9(27) concerning having infection with human immunodeficiency virus; • revising the factors in subsections 9(7) and 9(28) concerning having chronic renal failure; • revising the factors in subsections 9(8) and 9(29) concerning having leukaemia or lymphoma; • new factors in subsections 9(9) and 9(30) concerning taking a drug that causes neutropenia or agranulocytosis; • new factors in subsections 9(10) and 9(31) concerning having severe vitamin C deficiency; • new factors in subsections 9(11) and 9(32) concerning having a solid organ transplant, stem cell transplant or bone marrow transplant; • revising the factors in subsections 9(13) and 9(34) concerning using the combined oral contraceptive pill; • revising the factors in subsections 9(14) and 9(35) concerning having an autoimmune or mucocutaneous disease; |

SUMMARY OF CHANGES

- new factors in subsections 9(16) and 9(37) concerning having infection involving the affected region of the gums;
- revising the factors in subsections 9(17) and 9(38) concerning experiencing a category 1A stressor or a category 1B stressor, by the inclusion of a note;
- revising the factors in paragraphs 9(18)(a) and 9(39)(a) concerning having severe malnutrition, for acute necrotising ulcerative gingivitis only;
- revising the factors in paragraphs 9(18)(b) and 9(39)(b) concerning having smoked tobacco products, for acute necrotising ulcerative gingivitis only;
- new factors in paragraphs 9(18)(c) and 9(39)(c) concerning experiencing a category 2 stressor, for acute necrotising ulcerative gingivitis only;
- revising the factors in subsections 9(20) and 9(41) concerning having drug-induced gingival overgrowth;
- new factors in subsections 9(21) and 9(42) concerning being obese;
- deleting factors concerning having an oral piercing adjacent to the affected region of the gums;
- new definitions of 'allergen', 'being obese', 'BMI', 'category 2 stressor', 'chronic renal failure', 'combined oral contraceptive pill as specified', 'MRCA', 'one pack-year', 'severe vitamin C deficiency', 'significant other', 'specified list of autoimmune or mucocutaneous diseases' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'acute necrotising ulcerative gingivitis', 'category 1A stressor', 'category 1B stressor', 'corpse', 'eyewitness', 'irritant substance', 'relevant service' and 'trauma to the affected region of the gums' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a foreign body', 'a nutritional deficiency', 'an autoimmune and mucocutaneous disease from the specified list', 'an oral piercing', 'combined oral contraceptive pill' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

For BoP SoP (Instrument No. 18/2022)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'gingivitis' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsections 9(1) and 9(18) concerning being prevented from cleaning the teeth, including toothbrushing and interdental cleansing;
- revising the factor in subsections 9(2) and 9(19) concerning having a foreign body embedded in the affected region of the gums, by the inclusion of a note;
- revising the factor in subsections 9(3) and 9(20) concerning having trauma to the affected region of the gums;
- revising the factor in subsections 9(4) and 9(21) concerning having direct exposure of the affected area to an irritant substance, by the inclusion of a note;
- new factor in subsections 9(5) and 9(22) concerning having direct exposure of the affected area to an allergen;
- revising the factor in subsections 9(6) and 9(23) concerning having infection with human immunodeficiency virus;
- revising the factor in subsections 9(7) and 9(24) concerning having chronic renal failure;
- revising the factor in subsections 9(8) and (25) concerning having leukaemia or lymphoma;
- new factor in subsections 9(9) and 9(26) concerning taking a drug that causes neutropenia or agranulocytosis;
- new factor in subsections 9(10) and 9(27) concerning having severe vitamin C deficiency;
- new factor in subsections 9(11) and 9(28) concerning having stem cell transplant or bone marrow transplant;
- revising the factor in subsections 9(13) and 9(30) concerning using the combined oral contraceptive pill;
- revising the factor in subsections 9(14) and 9(31) concerning having an autoimmune or mucocutaneous disease;
- new factor in subsections 9(16) and 9(33) concerning having infection involving the affected region of the gums;
- revising the factor in subsections 9(17)(a) and 9(34)(a) concerning having severe malnutrition, for acute necrotising ulcerative gingivitis only;
- revising the factor in subsections 9(17)(b) and 9(34)(b) concerning having smoked tobacco products, for acute necrotising ulcerative gingivitis only;
- deleting the factors concerning having an oral piercing adjacent to the affected region of the gums;

SUMMARY OF CHANGES

| | | |
|-------------------------|---|--|
| | | <ul style="list-style-type: none"> • deleting the factors concerning experiencing a category 1A stressor or a category 1B stressor; • new definitions of 'allergen', 'chronic renal failure', 'MRCA', 'one pack-year', 'severe vitamin C deficiency' and 'VEA' in Schedule 1 - Dictionary; • revising the definitions of 'acute necrotising ulcerative gingivitis', 'combined oral contraceptive pill as specified', 'irritant substance', 'relevant service', 'specified list of autoimmune or mucocutaneous diseases' and 'trauma to the affected region of the gums' in Schedule 1 - Dictionary; and • deleting the definitions of 'a foreign body', 'a nutritional deficiency', 'an oral piercing' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'. <p>The determining of these Instruments finalises the investigation in relation to <i>gingivitis</i> as advertised in the Government Notices Gazette of 5 January 2021.</p> |
| <p>19 & 20/2022</p> | <p>malignant neoplasm of the colon and rectum</p> | <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>malignant neoplasm of the colorectum</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 19/2022)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the name of the condition from 'malignant neoplasm of the colorectum' to 'malignant neoplasm of the colon and rectum'; • revising the definition of 'malignant neoplasm of the colon and rectum' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factor in subsection 9(2) concerning having a colorectal adenoma, for clinical onset only; • new factor in subsection 9(3) concerning being prevented from accessing clinical screening for colorectal precancerous lesions or colorectal cancer in accordance with contemporary medical standards of the time, for clinical onset only; • new factor in subsection 9(4) concerning being prevented from accessing appropriate treatment for colorectal precancerous lesions in accordance with contemporary medical standards of the time, for clinical onset only; • new factor in subsection 9(5) concerning having inflammatory bowel disease, for clinical onset only; • new factor in subsection 9(6) concerning undergoing a course of therapeutic radiation for cancer, for clinical onset only; • revising the factor in subsection 9(7) concerning having received a cumulative equivalent dose of ionising radiation, by the inclusion of a note, for clinical onset only; • revising the factor in subsection 9(8) concerning inhaling respirable asbestos fibres in an enclosed space, for clinical onset only; • revising the factor in subsection 9(9) concerning inhaling respirable asbestos fibres in an open environment, for clinical onset only; • revising the factor in subsection 9(10) concerning having smoked tobacco products, for clinical onset only; • revising the factor in subsection 9(11) concerning consuming alcohol, for clinical onset only; • revising the factor in subsection 9(12) concerning being overweight or obese, for clinical onset only; • new factor in subsection 9(14) concerning having a solid organ transplant, for clinical onset only; • revising the factor in subsection 9(15) concerning having chronic schistosomiasis, for clinical onset only; • new factor in subsection 9(16) concerning having a ureterosigmoidostomy, for clinical onset only; • new factor in subsection 9(17) concerning having psoriasis, for clinical onset only; • new factor in subsection 9(18) concerning having sarcoidosis, for clinical onset only; • new factor in subsection 9(19) concerning having bilateral oophorectomy, for clinical onset only; • new factor in subsection 9(20) concerning having bilateral orchiectomy, for clinical onset only; |

SUMMARY OF CHANGES

- new factor in subsection 9(21) concerning having androgen deprivation therapy, for clinical onset only;
- revising the factor in subsection 9(22) concerning an inability to consume fibre, for clinical onset only;
- revising the factor in subsection 9(23) concerning an inability to consume dairy milk, for clinical onset only;
- revising the factor in paragraph 9(24)(a) concerning an inability to undertake physical activity, for malignant neoplasm of the colon only, for clinical onset only;
- revising the factor in paragraph 9(24)(b) concerning having acromegaly, for malignant neoplasm of the colon only, for clinical onset only;
- revising the factor in paragraph 9(24)(c) concerning consuming red meat, for malignant neoplasm of the colon only, for clinical onset only;
- revising the factor in paragraph 9(24)(d) concerning consuming processed meat product, for malignant neoplasm of the colon only, for clinical onset only;
- new factor in paragraph 9(24)(e) concerning an inability to consume fruit and vegetables, for malignant neoplasm of the colon only, for clinical onset only;
- new factor in paragraph 9(24)(f) concerning having a cholecystectomy, for malignant neoplasm of the colon only, for clinical onset only;
- deleting the factor concerning having ulcerative colitis as this is now covered by factor 9(5) concerning having inflammatory bowel disease;
- deleting the factor concerning having Crohn's disease as this is now covered by factor 9(5) concerning having inflammatory bowel disease;
- deleting the factor concerning an inability to consume folate in food;
- new definitions of 'being overweight or obese', 'BMI', 'colorectal precancerous lesions', 'cumulative equivalent dose', 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'red meat' and 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'alcohol', 'being obese', 'folate in food', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

For BoP SoP (Instrument No. 20/2022)

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the name of the condition from 'malignant neoplasm of the colorectum' to 'malignant neoplasm of the colon and rectum';
- revising the definition of 'malignant neoplasm of the colon and rectum' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(2) concerning having a colorectal adenoma, for clinical onset only;
- new factor in subsection 9(3) concerning being prevented from accessing clinical screening for colorectal precancerous lesions or colorectal cancer in accordance with contemporary medical standards of the time, for clinical onset only;
- new factor in subsection 9(4) concerning being prevented from accessing appropriate treatment for colorectal precancerous lesions in accordance with contemporary medical standards of the time, for clinical onset only;
- new factor in subsection 9(5) concerning having inflammatory bowel disease, for clinical onset only;
- new factor in subsection 9(6) concerning undergoing a course of therapeutic radiation for cancer, for clinical onset only;
- revising the factor in subsection 9(7) concerning having received a cumulative equivalent dose of ionising radiation, by the inclusion of a note, for clinical onset only;
- revising the factor in subsection 9(8) concerning inhaling respirable asbestos fibres in an enclosed space, for clinical onset only;
- revising the factor in subsection 9(9) concerning inhaling respirable asbestos fibres in an open environment, for clinical onset only;
- revising the factor in subsection 9(10) concerning having smoked tobacco products, for clinical onset only;
- revising the factor in subsection 9(11) concerning consuming alcohol, for clinical onset only;
- revising the factor in subsection 9(12) concerning being obese, for clinical onset only;
- revising the factor in subsection 9(14) concerning having chronic schistosomiasis, for clinical onset only;

SUMMARY OF CHANGES

- revising the factor in subsection 9(15) concerning an inability to consume fibre, for clinical onset only;
 - revising the factor in paragraph 9(16)(a) concerning an inability to undertake any physical activity, for malignant neoplasm of the colon only, for clinical onset only;
 - revising the factor in paragraph 9(16)(b) concerning having acromegaly, for malignant neoplasm of the colon only, for clinical onset only;
 - revising the factor in paragraph 9(16)(c) concerning consuming red meat, for malignant neoplasm of the colon only, for clinical onset only;
 - revising the factor in paragraph 9(16)(d) concerning consuming processed meat product, for malignant neoplasm of the colon only, for clinical onset only;
 - deleting the factor concerning having ulcerative colitis as this is now covered by factor 9(5) concerning having inflammatory bowel disease;
 - deleting the factor concerning having Crohn's disease as this is now covered by factor 9(5) concerning having inflammatory bowel disease;
 - deleting the factor concerning an inability to consume folate in food;
 - new definitions of 'BMI', 'colorectal precancerous lesions', 'cumulative equivalent dose', 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary;
 - revising the definitions of 'being obese', 'red meat' and 'relevant service' in Schedule 1 - Dictionary; and
 - deleting the definitions of 'alcohol', 'folate in food', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.
- The determining of these Instruments finalises the investigation in relation to *malignant neoplasm of the colorectum* as advertised in the Government Notices Gazette of 5 January 2021.**